Brokers Offer Predictions for Glaukos Corp’s FY2018 Earnings (GKOS)

Glaukos Corp (NYSE:GKOS) – Equities research analysts at William Blair lowered their FY2018 earnings per share (EPS) estimates for shares of Glaukos in a research note issued to investors on Monday, October 29th. William Blair analyst B. Weinstein now anticipates that the medical instruments supplier will post earnings of ($0.60) per share for the year, down from their previous forecast of ($0.57). William Blair also issued estimates for Glaukos’ Q4 2018 earnings at ($0.19) EPS, Q1 2019 earnings at ($0.09) EPS, Q2 2019 earnings at ($0.10) EPS, Q3 2019 earnings at ($0.10) EPS, Q4 2019 earnings at ($0.10) EPS and FY2019 earnings at ($0.40) EPS.

Other equities analysts have also issued reports about the stock. ValuEngine raised shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Zacks Investment Research raised shares of Glaukos from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Tuesday, August 7th. Berenberg Bank began coverage on shares of Glaukos in a research report on Thursday, August 30th. They set a “hold” rating and a $57.00 price target for the company. Stifel Nicolaus raised their price objective on shares of Glaukos from $32.00 to $35.00 and gave the stock a “hold” rating in a research note on Friday, August 3rd. Finally, BMO Capital Markets cut shares of Glaukos from an “outperform” rating to a “market perform” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, July 10th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $58.20.



GKOS opened at $57.94 on Thursday. Glaukos has a 12-month low of $23.08 and a 12-month high of $70.91.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The business had revenue of $43.16 million for the quarter, compared to analysts’ expectations of $40.51 million. During the same period in the prior year, the business posted ($0.10) earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year.

In related news, Director Gilbert H. Kliman sold 502,760 shares of Glaukos stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $60.39, for a total value of $30,361,676.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas William Burns sold 150,000 shares of Glaukos stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $38.78, for a total transaction of $5,817,000.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC grew its stake in Glaukos by 13.5% in the 2nd quarter. MetLife Investment Advisors LLC now owns 15,446 shares of the medical instruments supplier’s stock valued at $628,000 after acquiring an additional 1,838 shares during the period. Bank of Montreal Can grew its stake in Glaukos by 5.9% in the 3rd quarter. Bank of Montreal Can now owns 39,000 shares of the medical instruments supplier’s stock valued at $2,532,000 after acquiring an additional 2,190 shares during the period. Great West Life Assurance Co. Can grew its stake in Glaukos by 112.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock valued at $172,000 after acquiring an additional 2,240 shares during the period. Principal Financial Group Inc. grew its stake in Glaukos by 10.2% in the 1st quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock valued at $918,000 after acquiring an additional 2,746 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in Glaukos by 0.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 426,246 shares of the medical instruments supplier’s stock valued at $17,323,000 after acquiring an additional 2,845 shares during the period.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Read More: Analyst Ratings

Earnings History and Estimates for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply